Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Editas Medicine, Inc.
Editas Medicine to Participate in Upcoming Investor Conferences
August 28, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
August 07, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
July 31, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
June 14, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
June 14, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
May 14, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
May 10, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces First Quarter 2024 Results and Business Updates
May 08, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
May 02, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
May 01, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
BMY
EDIT
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
April 22, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
February 28, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
February 21, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine to Participate in Upcoming Investor Conferences
January 31, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
January 08, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
December 13, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
December 11, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
November 03, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
November 02, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
October 27, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
October 16, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
September 25, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
September 25, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Upcoming Investor Events
August 30, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
August 02, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
July 26, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
July 24, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
July 27, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Pricing of Offering of Common Stock
June 14, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.